CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Notable Labs Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Notable Labs Ltd
320 Hatch Drive
Phone: (415) 851-2410p:415 851-2410 FOSTER CITY, CA  94404  United States Ticker: NTBLNTBL

This company was Merged or Acquired on 10/16/2023.
This is a Subsidiary, click here for the Parent Company

Business Summary
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director Thomas A.Bock 59 10/16/2023 10/16/2023
Chief Financial Officer Scott A.Mcpherson 61 10/16/2023 10/16/2023
Senior Vice President - Research and Operations EyalBreitbart 55 2/1/2022 1/1/2006
12 additional Officers and Directors records available in full report.

Business Names
Business Name
NTBL
VBL Inc.
VBL Therapeutic
VBLT

General Information
Number of Employees: 7 (As of 3/1/2023)
Outstanding Shares: 9,018,261 (As of 2/15/2024)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 512899766
Fax Number: +972 89935001


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024